| Recruitment status | Terminated |
| Unique ID issued by UMIN | UMIN000039357 |
| Receipt No. | R000044769 |
| Scientific Title | Assessment of AMPA receptor density in patients with depression and bipolar disorder: a cross-sectional [11C]K-2 PET study |
| Date of disclosure of the study information | 2020/02/01 |
| Last modified on | 2020/08/07 (Ver. 2) |
| Basic information | ||
| Public title | Measurement of AMPA receptor density in patients with depression and bipolar disorder: a PET study | |
| Acronym | AMPA PET study in patients with depression and bipolar disorder | |
| Scientific Title | Assessment of AMPA receptor density in patients with depression and bipolar disorder: a cross-sectional [11C]K-2 PET study | |
| Scientific Title:Acronym | AMPA PET study in patients with depression and bipolar disorder | |
| Region |
|
|
| Condition | |||
| Condition | Depression; bipolar disorder | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | To identify brain regions that show association between AMPA receptor density and illness severity in patients with depression and bipolar disorder
|
| Basic objectives2 | Pharmacokinetics |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | Explanatory |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | AMPA receptor density and mood symptom scores in each of depression and bipolar disorder |
| Key secondary outcomes | Accuracy of differentiation of depression and bipolar disorder with the data collected in this study by using optimized machine learning program
Differences in AMPA receptor density in each voxel between depression and bipolar disorder Adverse events during 7 days after administration of [11C]K-2 |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | NO |
| Dynamic allocation | NO |
| Institution consideration | Institution is not considered as adjustment factor. |
| Blocking | NO |
| Concealment | No need to know |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Diagnosis | |
| Type of intervention |
|
|
| Interventions/Control_1 | Radiopharmaceutical [11C] K-2 is administered once, intravenously at 370 MBq for 1 minute. | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | (1) Fulfilling the criteria of depression or bipolar disorder according to the Structured Clinical Interview for DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), and International Statistical Classification of Diseases and Related Health Problems 10th Revison
(2) Being capable of providing informed consent |
|||
| Key exclusion criteria | (1) being pregnant or breast-feeding, or wishing to become pregnant, (2) being sensitive to alcohol, (3) comorbidity of serious neurological illness, (4) history of epilepsy, (5) use of perampanel or topiramate within 4 weeks, (6) history of substance use disorder for the past 6 months, (7) positive result on urine screening of substances that cause dependence, (8) having a metal object or pace maker in the body, (9) inappropriate size of head, neck, or body for MRI scan, (10) having large tatoo, (11) suffering from serious claustrophobia, (12) presence of significant brain anomaly, (13) abnormal lab results as follows: serum creatinine level of >=1.5, AST of >=150, or ALT of >=150, (14) having participated in any clinical trial that included the use of unapproved nuclear test within 6 months, (15) having participated in any other clinical trial that included intervention, (16) being judged to be inappropriate for participation by a study medical doctor | |||
| Target sample size | 60 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Yokohama City University Hospital
|
||||||
| Division name | Anesthesiology | ||||||
| Zip code | 236-0004 | ||||||
| Address | 3-9 Fukuura,Kanazawa-ku,Yokohama,Kanagawa,J apan | ||||||
| TEL | 045-787-2579 | ||||||
| johney4@hotmail.com | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Yokohama City University, School of Medicie | ||||||
| Division name | Physiology | ||||||
| Zip code | 236-0004 | ||||||
| Address | 3-9 Fukuura,Kanazawa-ku,Yokohama,Kanagawa,Japan | ||||||
| TEL | 045-787-2579 | ||||||
| Homepage URL | |||||||
| eirotuyosi@gmail.com | |||||||
| Sponsor | |
| Institute | Department of Physiology,Yokohama City University, School of Medicie |
| Institute | |
| Department | |
| Funding Source | |
| Organization | japan agency for medical research and development Strategic Research Program for Brain Science,Takeda Science Foundation,Yokohama City University Hospital advanded medical |
| Organization | |
| Division | |
| Category of Funding Organization | Non profit foundation |
| Nationality of Funding Organization | Japan |
| Other related organizations | |
| Co-sponsor | Keio University Hospital,Kyusyu University Hospital,Fukui University Hospital |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Yokohama City University Certified Institutional Review Board |
| Address | 3-9 Fukuura,Kanazawa-ku,Yokohama,Kanagawa,Japan |
| Tel | 045-370-7627 |
| ycu_crb@yokohama-cu.ac.jp | |
| Secondary IDs | |
| Secondary IDs | YES |
| Study ID_1 | jRCTs031190150 |
| Org. issuing International ID_1 | Japan Registry of Clinical Trials |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 横浜市立大学附属病院(神奈川県)、慶應義塾大学病院(東京都)、九州大学病院(福岡県)、福井大学病院(福井県) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Terminated | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Other | |
| Other related information | Because this study is described in the jRCT |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000044769 |